Wockhardt Valuation

Is WOCKPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WOCKPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate WOCKPHARMA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate WOCKPHARMA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WOCKPHARMA?

Key metric: As WOCKPHARMA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for WOCKPHARMA. This is calculated by dividing WOCKPHARMA's market cap by their current revenue.
What is WOCKPHARMA's PS Ratio?
PS Ratio	6.4x
Sales	₹29.81b
Market Cap	₹190.86b

WOCKPHARMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.2x
Enterprise Value/EBITDA	79.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does WOCKPHARMA's PS Ratio compare to its peers?

The above table shows the PS ratio for WOCKPHARMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.9x
CONCORDBIO Concord Biotech	19.2x	20.1%	₹208.3b
530019 Jubilant Pharmova	2.6x	10.3%	₹179.1b
PFIZER Pfizer	10.5x	9.2%	₹234.7b
APLLTD Alembic Pharmaceuticals	3.2x	11.0%	₹204.0b
WOCKPHARMA Wockhardt	6.4x	n/a	₹190.9b

Price-To-Sales vs Peers: WOCKPHARMA is good value based on its Price-To-Sales Ratio (6.4x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does WOCKPHARMA's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.5x	n/a	US$92.90m
539561 Remedium Lifecare	0.07x	n/a	US$29.56m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$19.63m
531173 Syschem (India)	0.5x	n/a	US$18.87m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: WOCKPHARMA is expensive based on its Price-To-Sales Ratio (6.4x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is WOCKPHARMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WOCKPHARMA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate WOCKPHARMA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

11.6%

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

-3.5%

18.7%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

-1.3%

-16.9%